{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:08Z","timestamp":1786980488794,"version":"build-2736575974"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s10067-021-05930-1","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T04:25:25Z","timestamp":1632803125000},"page":"297-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A historical journey of searching for uricosuric drugs"],"prefix":"10.1007","volume":"41","author":[{"given":"Tim LThA","family":"Jansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giesen","family":"Tanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janssen","family":"Matthijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"5930_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S11330","volume":"4","author":"SR Kingsbury","year":"2011","unstructured":"Kingsbury SR, Conaghan PG, McDermott MF (2011) The role of the NLRP3 inflammasome in gout. J Inflamm Res 4:39\u201349. https:\/\/doi.org\/10.2147\/JIR.S11330","journal-title":"J Inflamm Res"},{"key":"5930_CR2","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1136\/annrheumdis-2019-216233","volume":"79","author":"V Kl\u00fcck","year":"2020","unstructured":"Kl\u00fcck V, Van Deuren R, Cavalli G et al (2020) Rare genetic variants in the interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis 79:536\u2013544. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216233","journal-title":"Ann Rheum Dis"},{"key":"5930_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/1756-185X.12010","volume":"15","author":"KD Torraba","year":"2012","unstructured":"Torraba KD, De Jesus E, Rachabattula S (2012) The interplay between diet, urate transporters and the risk for gout and hyperuricemia: current and future directions. Int J Rheum Dis 15:499\u2013506","journal-title":"Int J Rheum Dis"},{"key":"5930_CR4","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839\u20131848","journal-title":"Ann Rheum Dis"},{"key":"5930_CR5","doi-asserted-by":"publisher","first-page":"e270","DOI":"10.1016\/s2665-9913(20)30065-5","volume":"2","author":"V Kl\u00fcck","year":"2020","unstructured":"Kl\u00fcck V, Jansen TL, Janssen M et al (2020) Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial. Lancet Rheumatol 2:e270\u2013e280. https:\/\/doi.org\/10.1016\/s2665-9913(20)30065-5","journal-title":"Lancet Rheumatol"},{"key":"5930_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E et al (2017) 2016 updated EULAR evidence-based recommendations fort he management of gout. Ann Rheum Dis 76:29\u201341. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209707","journal-title":"Ann Rheum Dis"},{"key":"5930_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/21054-3589(08)60098-8","volume":"4","author":"AB Gutman","year":"1966","unstructured":"Gutman AB (1966) Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol 4:91\u2013142. https:\/\/doi.org\/10.1016\/21054-3589(08)60098-8","journal-title":"Adv Pharmacol"},{"issue":"2","key":"5930_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2165\/00003088-198106020-00004","volume":"6","author":"RF Cunningham","year":"1981","unstructured":"Cunningham RF, Israili ZH, Dayton PG (1981) Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 6(2):135\u2013151. https:\/\/doi.org\/10.2165\/00003088-198106020-00004","journal-title":"Clin Pharmacokinet"},{"key":"5930_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3899\/jrheum.101160","volume":"38","author":"SL Stocker","year":"2011","unstructured":"Stocker SL, Graham GG, McLachlan AJ et al (2011) Pharmacokinetic and pharmacodynamics interaction between allopurinol and probenecid in patients with gout. J Rheumatol 38:904\u2013910","journal-title":"J Rheumatol"},{"key":"5930_CR10","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","volume":"26","author":"MK Reinders","year":"2007","unstructured":"Reinders MK, Van Roon EN, Houtman PM et al (2007) Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 26:1459\u20131465","journal-title":"Clin Rheumatol"},{"key":"5930_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/ard.2007.083071","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Van Roon EN, Jansen TL et al (2009) Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 68:51\u201356","journal-title":"Ann Rheum Dis"},{"key":"5930_CR12","first-page":"319","volume":"77","author":"WC Kuzell","year":"1952","unstructured":"Kuzell WC, Schaffarzick RW (1952) Phenylbutazone and butapyrin \u2014 a study of clinical effects in arthritis and gout. California Med 77:319\u2013325","journal-title":"California Med"},{"key":"5930_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0025-7125(16)31334-7","volume":"61","author":"JR Klinenberg","year":"1977","unstructured":"Klinenberg JR (1977) Hyperuricemia and gout. Med Clin North Am 61:299\u2013312","journal-title":"Med Clin North Am"},{"key":"5930_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1185\/03007998009109465","volume":"6","author":"JA Reardon","year":"1980","unstructured":"Reardon JA, Stockman A, Darlington LG, Scott JT (1980) Double blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 6:445\u2013448","journal-title":"Curr Med Res Opin"},{"key":"5930_CR15","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1055\/s-0028-1114025","volume":"87","author":"H Von Rechenberg","year":"1962","unstructured":"Von Rechenberg H (1962) Side-effects of phenylbutazone. Dtsch Med Wochenschr 87:1812","journal-title":"Dtsch Med Wochenschr"},{"key":"5930_CR16","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJM195805012581808","volume":"258","author":"EB Reed","year":"1958","unstructured":"Reed EB, Feichtmeir TV, Willett FM (1958) Zoxazolamine \u2014 a potent uricosuric agent. NEJM 258:894\u2013896","journal-title":"NEJM"},{"key":"5930_CR17","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJM195706202562508","volume":"256","author":"T Cohen","year":"1957","unstructured":"Cohen T (1957) Nephropathy associated with oral administration of zoxazolamine (Flexin): report of case. NEJM 256:1193","journal-title":"NEJM"},{"key":"5930_CR18","first-page":"419","volume":"34","author":"H Jasper","year":"1960","unstructured":"Jasper H (1960) Jaundice in a patient receiving zoxazolamine (Flexin). Am J Gastroenterol 34:419\u2013421","journal-title":"Am J Gastroenterol"},{"key":"5930_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/jama.1961.63040230010013a","volume":"176","author":"HB Eisenstadt","year":"1961","unstructured":"Eisenstadt HB, Elster BB (1961) Zoxazolamine hepatitis. JAMA 176:874\u2013876","journal-title":"JAMA"},{"key":"5930_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM196105112641905","volume":"264","author":"HJ Carr","year":"1961","unstructured":"Carr HJ, Knauer QF (1961) Death due to hepatic necrosis in a patient receiving zoxazolamine. Report of a case and review of the literature. NEJM 264:977\u2013980","journal-title":"NEJM"},{"key":"5930_CR21","doi-asserted-by":"crossref","unstructured":"Yu H, Liu X, Song Y et al. (2018) Safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with chronic kidney disease: a prospective pilot study. Clin Exp Nephrology 22","DOI":"10.1007\/s10157-018-1586-y"},{"key":"5930_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0049-3848(84)90106-3","volume":"34","author":"M Cortellaro","year":"1984","unstructured":"Cortellaro M, Boschetti C, Antoniazzi V et al (1984) A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers. Thromb Res 34:65\u201374","journal-title":"Thromb Res"},{"key":"5930_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1172\/JCI107323","volume":"52","author":"HS Diamond","year":"1973","unstructured":"Diamond HS, Paolino JS (1973) Evidence for a post-secretory reabsorptive site for uric acid in man. J Clin Invest 52:1491\u20131499","journal-title":"J Clin Invest"},{"key":"5930_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/009286150103500134","volume":"35","author":"M Fung","year":"2001","unstructured":"Fung M, Thornton A, Mybeck K, Wu J, Hornbuckle K, Muniz E (2001) Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960-1999. Drug Information Journal 35:293\u2013317","journal-title":"Drug Information Journal"},{"key":"5930_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-080-x","volume":"59","author":"VF Azevedo","year":"2019","unstructured":"Azevedo VF, Kos IA, Vargas-Santos AB et al (2019) Benzbromarone in the treatment of gout Adv. Rheumatol 59:37. https:\/\/doi.org\/10.1186\/s42358-019-080-x","journal-title":"Rheumatol"},{"key":"5930_CR26","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1136\/ard.2008.091462","volume":"68","author":"MK Reinders","year":"2009","unstructured":"Reinders MK, Haagsma C, Jansen TL et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300\u2013600 mg\/day versus benzbromarone 100\u2013200 mg\/day in patients with gout. Ann Rheum Dis 68:892\u2013897","journal-title":"Ann Rheum Dis"},{"key":"5930_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","volume":"21","author":"N Liang","year":"2019","unstructured":"Liang N, Sun M, Sun R et al (2019) Baseline urate level and renal function predict outcomes of urate-lowering therapy using low-doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chines primary gout cohort. Arthritis Res & Ther 21:200. https:\/\/doi.org\/10.1186\/s13075-019-1976-x","journal-title":"Arthritis Res & Ther"},{"key":"5930_CR28","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/imj.13173","volume":"46","author":"LK Stamp","year":"2016","unstructured":"Stamp LK, Haslett J, Frampton C et al (2016) The safety and efficacy of benzbromarone in gout in Aotearoa New Zealand. Int Med J 46:1075\u20131080","journal-title":"Int Med J"},{"key":"5930_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF00548587","volume":"19","author":"H Ferber","year":"1981","unstructured":"Ferber H, Vergin H, Hitzenberger G (1981) Pharmacokinetics and biotransformation of benzbromarone in man. Eur J Clin Pharmacol 19:431\u2013435. https:\/\/doi.org\/10.1007\/BF00548587","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"5930_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2133\/dmpk.dmpk-10.nt-040","volume":"25","author":"S Uchida","year":"2010","unstructured":"Uchida S, Shimada K, Misaka S et al (2010) (2010) Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 25(6):605\u2013610. https:\/\/doi.org\/10.2133\/dmpk.dmpk-10.nt-040","journal-title":"Drug Metab Pharmacokinet"},{"key":"5930_CR31","first-page":"651","volume":"22","author":"TLThA Jansen","year":"2004","unstructured":"Jansen TLThA, Reinders MK, Van Roon EN, Brouwers JRBJ (2004) Benzbromarone withdrawn from the European market: another case of \u201c absence of evidence is evidence of absence\u201d? Clin Exp Rheumatol 22:651\u2013652","journal-title":"Clin Exp Rheumatol"},{"key":"5930_CR32","unstructured":"Hotea I, Janssen M, Jansen TL. (2021) The uricosuric benzbromarone in real life gout patients. Submitted"},{"key":"5930_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/rheumatology\/23.1.44","volume":"23","author":"T Gibson","year":"1984","unstructured":"Gibson T, Simmonds HA, Armstrong RD et al (1984) Azapropazone \u2014 a treatment for hyperuricemia and gout? Br J Rheumatology 23:44\u201351","journal-title":"Br J Rheumatology"},{"key":"5930_CR34","first-page":"149","volume":"6","author":"AL Thomas","year":"1983","unstructured":"Thomas AL, Majoos FL, Nuki G (1983) Preliminary studies with azapropazone in gout and hyperuricemia. Eur J Rheumatol Inflamm 6:149\u2013154","journal-title":"Eur J Rheumatol Inflamm"},{"key":"5930_CR35","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1365-2125.1984.tb02486.x","volume":"18","author":"CS Higgens","year":"1984","unstructured":"Higgens CS, Scott JT (1984) The uricosuric action of azapropazone: dose-response and comparison with probenecid. Br J Clin Pharmacol 18:439\u2013443","journal-title":"Br J Clin Pharmacol"},{"key":"5930_CR36","first-page":"409","volume":"37","author":"RC Fraser","year":"1987","unstructured":"Fraser RC, Davus RH, Walker FS (1987) Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia. J R Coll Gen Pract 37:409\u2013411","journal-title":"J R Coll Gen Pract"},{"key":"5930_CR37","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1001\/jama.1979.03300260046029","volume":"242","author":"ME Kosman","year":"1979","unstructured":"Kosman ME (1979) Evaluation of a new uricosuric diuretic \u2014 ticrynafen. JAMA 242:2876\u201378","journal-title":"JAMA"},{"key":"5930_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1159\/000181668","volume":"23","author":"AK Jain","year":"1979","unstructured":"Jain AK, Ryan JR, McMahon FG (1979) Comparison of ticrynafen and probenecid in patients with elevated uric acid levels. Nephron 23:46\u201350","journal-title":"Nephron"},{"key":"5930_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1136\/ard.39.4.367","volume":"39","author":"JA Reardon","year":"1980","unstructured":"Reardon JA, Scott JT (1980) Controlled inpatient study of tienilic acid in treatment of gout and hypertension. Ann Rheum Dis 39:367\u2013372","journal-title":"Ann Rheum Dis"},{"key":"5930_CR40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.1840040223","volume":"4","author":"HJ Zimmerman","year":"1984","unstructured":"Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC (1984) Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology 4:315\u2013323","journal-title":"Hepatology"},{"key":"5930_CR41","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s10067-016-3273-2","volume":"35","author":"P Dua","year":"2016","unstructured":"Dua P, Gurrell R, Kirby S, Sudworth M, Loudon PT (2016) Acute kidney injury observed during phase 1 trials of a novel xanthine oxidase\/URAT1 dual inhibitor PF-06743649. Clinical Rheumatol 35:2045\u20132051","journal-title":"Clinical Rheumatol"},{"key":"5930_CR42","doi-asserted-by":"publisher","unstructured":"Miner JN, Tan PK, Hyndman D et al. (2016) Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney. Arthritis Res & Ther. https:\/\/doi.org\/10.1186\/s13075-016-1107-x.","DOI":"10.1186\/s13075-016-1107-x"},{"key":"5930_CR43","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1002\/art.40159","volume":"69","author":"N Dalbeth","year":"2017","unstructured":"Dalbeth N, Jones G, Terkeltaub R et al (2017) Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial. Arthritis & Rheum 69:1903\u20131913","journal-title":"Arthritis & Rheum"},{"key":"5930_CR44","first-page":"811","volume":"76","author":"T Bardin","year":"2017","unstructured":"Bardin T, Keenen RT, Khanna PP et al (2017) Lesinurad in combination with allopurinol: a randomised, double-blind, placebo controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR2 study). ARD 76:811\u2013820","journal-title":"ARD"},{"key":"5930_CR45","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s10067-018-4306-9","volume":"37","author":"TL Jansen","year":"2018","unstructured":"Jansen TL, Perez-Ruiz F, Tausche AK, Richette P (2018) International position paper on the appropriate use of uricosurics with the introduction of Lesinurad. Clin Rheumatol 37:3159\u20133165","journal-title":"Clin Rheumatol"},{"key":"5930_CR46","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N et al (2017) Lesinurad monotherapy in gout patients intolerant to xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology 56:2170\u20132178","journal-title":"Rheumatology"},{"key":"5930_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T et al (2020) Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicentre, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol 24:53\u201361","journal-title":"Clin Exp Nephrol"},{"key":"5930_CR48","doi-asserted-by":"publisher","first-page":"e2347","DOI":"10.1210\/clinem\/dgaa748","volume":"106","author":"AG Stack","year":"2021","unstructured":"Stack AG, Han D, Goldwater R et al (2021) Dapaglifozin added to verinurad plus febuxostat further reduces serum uric acid in hyperuricemia: the Quartz study. J Clin Endocrinol Metab 106:e2347\u2013e2356","journal-title":"J Clin Endocrinol Metab"},{"key":"5930_CR49","first-page":"e14428","volume":"13","author":"A Iqbal","year":"2021","unstructured":"Iqbal A, Iqbal K, Farid E et al (2021) Efficacy and safety of dotinurad in hyperuricemic patients with or without gout: a systematic review and meta-analysis of randomized controlled trials. Cureus 13:e14428","journal-title":"Cureus"},{"key":"5930_CR50","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/rheumatology\/key100","volume":"57","author":"M Shiramoto","year":"2018","unstructured":"Shiramoto M, Liu S, Shen Z et al (2018) Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study. Rheumatology 57:1602\u20131610","journal-title":"Rheumatology"},{"key":"5930_CR51","doi-asserted-by":"publisher","first-page":"44","DOI":"10.7326\/0003-4819-91-1-44","volume":"91","author":"PA Simkin","year":"1979","unstructured":"Simkin PA, Hoover PL, Paxson CS et al (1979) Uric acid excretion: quantitative assessment from spot, midmorning serum and urine samples. Ann Intern Med 91:44\u201347","journal-title":"Ann Intern Med"},{"key":"5930_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/ar3191","volume":"12","author":"PL Indranata","year":"2010","unstructured":"Indranata PL, Stocker SL, Williams KM et al (2010) A proposal for identifying the low renal uric acid clearance phenotype. Arthritis Res & Ther 12:149","journal-title":"Arthritis Res & Ther"},{"key":"5930_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00716361","volume":"13","author":"B Pfister","year":"1978","unstructured":"Pfister B, Imhof P, Wirz H (1978) Effect of sulfinpyrazone on uric acid excretion and plasma uric acid concentration in healthy volunteers. Eur J Clin Pharmacol 13:263\u2013265","journal-title":"Eur J Clin Pharmacol"},{"key":"5930_CR54","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","volume":"31","author":"M-HH Lee","year":"2008","unstructured":"Lee M-HH, Graham GG, Williams KM, Day O, R. (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was withdrawal from the market in the best interest of patients? Drug Saf 31:643\u2013665","journal-title":"Drug Saf"},{"key":"5930_CR55","first-page":"e7762","volume":"12","author":"V Bassi","year":"2020","unstructured":"Bassi V, Fattoruso O (2020) The role of fractional excretion of uric acid in the differential diagnosis of hypotonic hyponatraemia in patients with diuretic therapy. Cureus 12:e7762","journal-title":"Cureus"},{"key":"5930_CR56","first-page":"1207","volume":"28","author":"PA Simkin","year":"2001","unstructured":"Simkin PA (2001) When, why, and how should we quantify the excretion rate of urinary uric acid? J of Rheumatol 28:1207\u20131210","journal-title":"J of Rheumatol"},{"key":"5930_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14656566.2015.997213","volume":"16","author":"PC Robinson","year":"2014","unstructured":"Robinson PC, Dalbeth N (2014) Advances in pharmacotherapy for the treatment of gout. Expert Opinion Pharmacother 16:1\u201314. https:\/\/doi.org\/10.1517\/14656566.2015.997213","journal-title":"Expert Opinion Pharmacother"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05930-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05930-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05930-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T19:36:02Z","timestamp":1675712162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05930-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5930"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05930-1","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}